{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T08:36:07Z","timestamp":1648974967800},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1097\/gco.0b013e328334e43b","type":"journal-article","created":{"date-parts":[[2009,12,24]],"date-time":"2009-12-24T08:17:17Z","timestamp":1261642637000},"page":"61-66","source":"Crossref","is-referenced-by-count":0,"title":["Bisphosphonates: ready for use as adjuvant therapy of breast cancer?"],"prefix":"10.1097","volume":"22","author":[{"given":"Richard L","family":"Theriault","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-12-20210129","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"NEJM"},{"key":"R2-12-20210129","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4161\/cbt.7.1.5163","article-title":"Biology of breast cancer bone metastasis","volume":"7","author":"Akhtari","year":"2008","journal-title":"Cancer Biol Ther"},{"key":"R3-12-20210129","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1191\/0269216304pm914ra","article-title":"Systematic review of bisposphonates for hypercalcemia of malignancy","volume":"18","author":"Saunders","year":"2004","journal-title":"Palliat Med"},{"key":"R4-12-20210129","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"N Engl J Med"},{"key":"R5-12-20210129","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","article-title":"Term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast cancer Study Group","volume":"16","author":"Hortobagyi","year":"1998","journal-title":"J Clin Oncol"},{"key":"R6-12-20210129","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","article-title":"Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group","volume":"17","author":"Theriault","year":"1999","journal-title":"J Clin Oncol"},{"key":"R7-12-20210129","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long-term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"R8-12-20210129","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00044011-200626060-00002","article-title":"Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial","volume":"26","author":"Pecherstorfer","year":"2006","journal-title":"Clin Drug Investig"},{"key":"R9-12-20210129","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"R10-12-20210129","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","article-title":"Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"R11-12-20210129","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/j.clinthera.2004.12.010","article-title":"Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials","volume":"26","author":"Tripathy","year":"2004","journal-title":"Clin Ther"},{"key":"R12-12-20210129","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/bmj.327.7413.469","article-title":"Review: bisphosphonates reduce fractures, radiotherapy, and hypercalcemia and increase time to a first skeletal related event","volume":"327","author":"Ross","year":"2003","journal-title":"BMJ"},{"key":"R13-12-20210129","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1470-2045(07)70003-7","article-title":"Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomized controlled study","volume":"8","author":"Coleman","year":"2007","journal-title":"Lancet Oncol"},{"key":"R14-12-20210129","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.2007.11.0726","article-title":"Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230","volume":"26","author":"Eastell","year":"2008","journal-title":"J Clin Oncol"},{"key":"R15-12-20210129","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/annonc\/mdp033","article-title":"Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial","volume":"20","author":"Rabaglio","year":"2009","journal-title":"Ann Oncol"},{"key":"R16-12-20210129","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1200\/JCO.2008.18.4184","article-title":"Cancer treatment-induced bone loss in breast and prostate cancer","volume":"26","author":"Saad","year":"2008","journal-title":"J Clin Oncol"},{"key":"R17-12-20210129","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1016\/S0959-8049(01)00317-3","article-title":"Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment","volume":"37","author":"Vehmanen","year":"2001","journal-title":"Eur J Cancer"},{"key":"R18-12-20210129","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jnci\/90.9.704","article-title":"Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer","volume":"90","author":"Powles","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"R19-12-20210129","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.1200\/JCO.2007.15.4997","article-title":"Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer","volume":"26","author":"Saarto","year":"2008","journal-title":"J Clin Oncol"},{"key":"R20-12-20210129","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1200\/JCO.2007.15.2967","article-title":"Risedronate prevents bone loss in breast cancer survivors: a two year, randomized, double-blind, placebo-controlled clinical trial","volume":"26","author":"Greenspan","year":"2008","journal-title":"J Clin Oncol"},{"key":"R21-12-20210129","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.1997.15.3.955","article-title":"Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study","volume":"15","author":"Delmas","year":"1997","journal-title":"J Clin Oncol"},{"key":"R22-12-20210129","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1200\/JCO.2008.19.1783","article-title":"Phase III randomized, placebo-controlled, double blind trial of risedronate for prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer","volume":"27","author":"Hines","year":"2008","journal-title":"J Clin Oncol"},{"key":"R23-12-20210129","doi-asserted-by":"crossref","first-page":"6336","DOI":"10.1158\/1078-0432.CCR-07-5101","article-title":"Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer","volume":"14","author":"Lester","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R24-12-20210129","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","article-title":"Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer","volume":"25","author":"Brufsky","year":"2007","journal-title":"J Clin Oncol"},{"key":"R25-12-20210129","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1200\/JCO.2008.16.4707","article-title":"Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer","volume":"26","author":"Hershman","year":"2008","journal-title":"J Clin Oncol"},{"key":"R26-12-20210129","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/cncr.23259","article-title":"Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in poatmenopausal women with early beast cancer receiving adjuvant letrozole ZO_FAST Study Results","volume":"112","author":"Bundred","year":"2008","journal-title":"Cancer"},{"key":"R27-12-20210129","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3816\/CBC.2009.n.015","article-title":"Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results","volume":"9","author":"Brufsky","year":"2009","journal-title":"Clin Breast Cancer"},{"key":"R28-12-20210129","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1634\/theoncologist.2007-0206","article-title":"Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole","volume":"13","author":"Brufsky","year":"2008","journal-title":"Oncologist"},{"key":"R29-12-20210129","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N Engl J Med"},{"key":"R30-12-20210129","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","article-title":"Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists Group, Forbes JF, Cuzick J, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.","volume":"9","year":"2008","journal-title":"Lancet Oncol"},{"key":"R31-12-20210129","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/annonc\/mdm566","article-title":"Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17","volume":"19","author":"Ingle","year":"2008","journal-title":"Ann Oncol"},{"key":"R32-12-20210129","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","article-title":"Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98","volume":"25","author":"Coates","year":"2007","journal-title":"J Clin Oncol"},{"key":"R33-12-20210129","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ncponc0520","article-title":"Mechanisms of disease: preclinical reports of antineoplastic synergistic action of bisphosphonates","volume":"3","author":"Santini","year":"2006","journal-title":"Nature Clin Pract Oncol"},{"key":"R34-12-20210129","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ctrv.2008.02.004","article-title":"Exploring the anticancer activity of bisphosphonates in early breast cancer","volume":"34","author":"Winter","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"R35-12-20210129","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejphar.2007.05.075","article-title":"Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells","volume":"570","author":"Merrell","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"R36-12-20210129","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.2174\/092986707781389600","article-title":"Zoledronic acid: a multiplicity of anticancer action","volume":"14","author":"Yuasa","year":"2007","journal-title":"Curr Med Chem"},{"key":"R37-12-20210129","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00001813-200501000-00002","article-title":"Preclinical evidence for the effect of bisphosphonates and cytotoxic drugs on tumor cell invasion","volume":"16","author":"Woodward","year":"2005","journal-title":"Anticancer Drugs"},{"key":"R38-12-20210129","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/annonc\/mdn429","article-title":"Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up","volume":"19","author":"Diel","year":"2008","journal-title":"Ann Oncol"},{"key":"R39-12-20210129","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/bcr1384","article-title":"Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]","volume":"8","author":"Powles","year":"2006","journal-title":"Breast Cancer Res"},{"key":"R40-12-20210129","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/02841860410032885","article-title":"Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients","volume":"43","author":"Saarto","year":"2004","journal-title":"Acta Oncol"},{"issue":"Suppl 1","key":"R41-12-20210129","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ctrv.2008.03.007","article-title":"Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group","volume":"34","author":"Reid","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"R42-12-20210129","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Ann Oncol"},{"key":"R43-12-20210129","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/annonc\/mdn164","article-title":"Practical guidance for the management of aromatase inhibitor-associated bone loss","volume":"19","author":"Hadji","year":"2008","journal-title":"Ann Oncol"},{"key":"R44-12-20210129","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s00198-007-0439-4","article-title":"Management of cancer treatment-induced bone loss in early breast and prostate cancer: a consensus paper of the Belgian Bone Club","volume":"18","author":"Body","year":"2007","journal-title":"Osteoporos Int"},{"key":"R45-12-20210129","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society Of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol"}],"container-title":["Current Opinion in Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/GCO.0b013e328334e43b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:16:17Z","timestamp":1620951377000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001703-201002000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/gco.0b013e328334e43b","relation":{},"ISSN":["1040-872X"],"issn-type":[{"value":"1040-872X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}